Biomarin Pharmaceutical (BMRN) Cash from Investing Activities (2009 - 2026)

Biomarin Pharmaceutical has disclosed Cash from Investing Activities across 18 years of filings, most recently posting $725.5 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 2669.33% year-over-year to $725.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $339.5 million (up 177.19% YoY) and the FY2025 annual result came in at -$414.2 million, down 403.49% from the prior year.
• Cash from Investing Activities improved to $725.5 million in Q1 2026, from -$42.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $725.5 million in Q1 2026 and troughed at -$331.0 million in Q3 2025.
• A 5-year average of $18.6 million and a median of -$23.4 million in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2025 — Cash from Investing Activities slumped 1948.42% — and 2026, when it surged 2669.33%.
• Tracing BMRN's Cash from Investing Activities over 5 years: stood at -$54.7 million in 2022, then slipped by 18.74% to -$65.0 million in 2023, then jumped by 217.61% to $76.4 million in 2024, then slumped by 155.56% to -$42.4 million in 2025, then soared by 1809.18% to $725.5 million in 2026.
• Business Quant data shows BMRN's Cash from Investing Activities at $725.5 million in Q1 2026, -$42.4 million in Q4 2025, and -$331.0 million in Q3 2025.